# cellectis 

## Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

Listing market: NYSE Euronext Paris
ISIN code: FR0010425595

| Date | Total number of shares <br> in the capital | Total number of voting rights |
| :---: | :---: | :---: |
| $05 / 31 / 2017$ | $35,385,060$ | $40,663,086$ |

## About Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing - built on its flagship TALEN® technology and pioneering electroporation system PulseAgile - Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.

For further information, please contact:

## Media contacts:

Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, ckasunich@kcsa.com

## IR contact:

Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,
simon.harnest@cellectis.com

## Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

## \# \# \#

